PMID: 7537284Feb 1, 1995Paper

Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients

Journal of Clinical Psychopharmacology
L FardeB Ericsson

Abstract

By the use of positron emission tomography (PET), high central dopamine D2 receptor occupancy (70 to 90%) has been demonstrated in patients treated with conventional neuroleptics. In patients treated with the atypical antipsychotic clozapine, the D2 occupancy was low (20 to 67%). The effects of clozapine may thus be mediated by a mechanism distinct from D2 occupancy. The observation that low doses of clozapine (125 to 175 mg daily) induced more than 80% (5-hydroxytryptamine) 5-HT2 occupancy supports the view that 5-HT2 antagonism may be related to the atypical effects of clozapine. Risperidone is a new antipsychotic drug with high affinity in vitro for both central 5-HT2 and D2 receptors. In this study, we determined the D2 and 5-HT2 occupancy induced by clinical treatment with risperidone. Four patients with acute exacerbation of schizophrenia were examined by PET after 4 weeks of treatment with risperidone, 6 mg daily. The D2 occupancy in the striatum was 75 to 80%. The 5-HT2 occupancy in the neocortex was 78 to 88%. This study confirms that, in patients with schizophrenia, treatment with risperidone induces a high D2 and 5-HT2 occupancy. Risperidone is, accordingly, a suitable drug for the examination of the clinical benefit...Continue Reading

Citations

Aug 1, 1996·European Journal of Nuclear Medicine·G F Busatto
Jan 1, 1996·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·L J BeerpootD R Weinberger
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Shitij Kapur, David Mamo
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Herbert Y MeltzerJunji Ichikawa
Dec 4, 1998·Biological Psychiatry·J A LiebermanJ E Kraus
Aug 25, 2000·Progress in Neuro-psychopharmacology & Biological Psychiatry·R BruggemanW Timmerman
Nov 28, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Helen Rosengarten, David Quartermain
Feb 19, 1998·Schizophrenia Research·J L WaddingtonE O'Callaghan
Dec 7, 2002·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Peter S Talbot, Marc Laruelle
Apr 23, 2003·Drug Discovery Today·William C Eckelman
Jan 1, 1995·Acta Psychiatrica Scandinavica. Supplementum·W W Fleischhacker
Jul 21, 1998·Journal of Affective Disorders·M A FryeR M Post
Jul 12, 2011·Expert Opinion on Investigational Drugs·Bjørn H EbdrupBirte Glenthøj
Mar 25, 2009·Pharmacology & Therapeutics·Sarah Grimwood, Paul R Hartig
Feb 20, 2009·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Hiroyuki UchidaDavid C Mamo
Nov 15, 2011·Acta Psychiatrica Scandinavica·D M TaylorJ Nielsen
Mar 26, 2016·Progress in Neurobiology·Philippe De Deurwaerdère, Giuseppe Di Giovanni
Dec 6, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Rossella MedoriGerhard Gründer
Apr 29, 1998·The Psychiatric Clinics of North America·R J McClureJ W Pettegrew
Mar 18, 2004·Neuroimaging Clinics of North America·David ErritzoeAnissa Abi-Dargham
Sep 14, 2014·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Hiroyuki UchidaDavid C Mamo
Jun 4, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Takashi TsuboiHiroyuki Uchida
Nov 21, 1998·The European Journal of Neuroscience·P O TremblayC Rouillard
Nov 18, 2005·International Review of Neurobiology·W Gordon FrankleMarc Laruelle
Aug 8, 1998·Acta Psychiatrica Scandinavica·R S Shiwach, T J Carmody
Feb 1, 2012·Schizophrenia Bulletin·Hitoshi SakuraiHiroyuki Uchida
Sep 22, 2005·Journal of Psychopharmacology·Niina Ezewuzie, David Taylor
Jan 1, 1999·International Journal of Psychiatry in Clinical Practice·D Lecompte, R F Cookson
Dec 14, 2002·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Siegfried KasperThomas Brücke
Jan 1, 1997·Journal of Psychopharmacology·G F Busatto, R W Kerwin

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.